Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.
Sympascho YoungWei LiuKatherine ZukotynskiGlenn BaumanPublished in: Expert review of anticancer therapy (2021)
Through enhanced spatial characterization of recurrent prostate cancer, PSMA-targeted PET/CT has shown significant impact on management decisions. In particular, by identifying men with recurrence confined to the prostate or pelvic nodes, PSMA-targeted PET/CT enables selective deployment of localized salvage therapies for management of biochemical failure after primary treatment with prostatectomy or radiotherapy. In oligometastatic disease, PSMA-targeted PET/CT may improve patient selection and treatment accuracy for metastasis-directed therapy and early phase II studies show encouraging results in delaying the need for systemic therapy. Further, quantitative PSMA-targeted PET/CT for monitoring response and therapeutic PSMA-targeted radiopharmaceuticals are emerging as encouraging treatment options in the setting of castrate-resistant disease.
Keyphrases
- pet ct
- prostate cancer
- cancer therapy
- positron emission tomography
- radical prostatectomy
- clinical trial
- benign prostatic hyperplasia
- open label
- randomized controlled trial
- high resolution
- bone marrow
- rectal cancer
- squamous cell carcinoma
- computed tomography
- combination therapy
- robot assisted
- study protocol
- case control